Good news! NICE approves Ocrevus (ocrelizumab) for primary progressive MS

10 May 2019

Source MS Trust: The MS Trust is delighted that Ocrevus (ocrelizumab) has been approved by NICE for NHS treatment of early, inflammatory primary progressive MS.

NICE has approved Ocrevus for people with primary progressive MS if they:

  • have had symptoms of primary progressive MS for 15 years or less and
  • are able to walk 20 metres or more, with or without walking aids (up to EDSS 6.5) and
  • have evidence of MS activity on MRI scans

This reverses an earlier decision by NICE to reject Ocrevus for PPMS. The final publication of this decision was paused to allow time for further discussions to take place between NICE, NHS England and drug manufacturer Roche.  Read on.

Blog categories: 

Category

Archive